TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) could be one of the best stocks that investors may want to consider for their portfolio today as the company shares are trading 4.39% or 0.17 points up from last closing price of $3.87, reaching $4.04 at last check. Any clue why there is so much of action in the TCON stock? The share price has risen in 2 of the last 5 days and is down -8.38% over the past week. It will be exciting to see whether the stock manages to continue increasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -153,798 shares, and in total 128102 shares valued at $517532 were seen changing hands compared with 281900 shares valued at $1.091 million recorded at the previous session. You should take into consideration that a falling volume on higher prices causes divergence and may be an early warning about possible changes in TCON stock for the next couple of days.

TRACON Pharmaceuticals, Inc. (TCON) shares have notched a 3-month decline of about -8.38%, but has still advanced 65.38% year to date. By comparison, the stock sank -59.79% over the past 12 months, while it jumped 54.8% over the 1 month. The company’s market cap is around $12.81M, with its short interest ratio standing at 0.11%.

In the current trading session for TCON, the stock witnessed two major price actions, it rose to a high of $4.09 and was down as much as $3.9 at one point. The high recorded is very low when compared to their 52-week high which is $2.07. The 52-week high is now at -76.36 distance from current price. Their recent low of $17.3 represents a 97.58% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for TCON is $13, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.

TCON‘s last price was down -13.84% as compared to the average trading price of 50 days recorded at $4.69 while enlarging the period to 200 trading days, the average closing price was $3.09. At present, there are 3.31 million in the total number of common shares owned by the public and among those 3.02 million shares have been available to trade. The percentage of shares being held by the company management was 0.7% while institutions stake was 59.2%. The company has generated negative returns on equity over the last 12 months (-215.4%). It managed to keep its gross profit margin at 0% over the past 12 months.

When assessing the full upside of the TCON stock, there is another set of technicals that should be looked into and considered. Its 14.47% gain from moving average of $3.53 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 2.2 to the stock. With the beta been greater than one, this implies that the company shares are theoretically more volatile than the market, something that the traders definitely are keeping an eye on.

Most of the analysts surveyed by Thomson/First Call think quite highly of TRACON Pharmaceuticals, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $12.5 on shares of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), which corresponds to 207.13% upside potential than its current market price of $4.04 and implies potential despite the recent advance in the price. However, their current target price has fallen from $12.5 a month ago and is up handily from the consensus target of $6 a quarter ago.

In the last five years, the EPS of the company has been roughly -14.3%. Though the percentage looks disappointing, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.